Edition:
India

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

24.91USD
2:29am IST
Change (% chg)

$-0.56 (-2.20%)
Prev Close
$25.47
Open
$25.66
Day's High
$25.80
Day's Low
$24.82
Volume
292,858
Avg. Vol
337,097
52-wk High
$32.22
52-wk Low
$16.51

Chart for

About

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $954.94
Shares Outstanding(Mil.): 31.91
Dividend: --
Yield (%): --

Financials

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

08 Dec 2017

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

07 Nov 2017

BRIEF-Flexion Therapeutics announces pricing of public offering of common stock

* Flexion Therapeutics announces pricing of public offering of common stock

12 Oct 2017

BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

* Flexion Therapeutics announces proposed public offering of common stock

11 Oct 2017

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

07 Oct 2017

UPDATE 2-Flexion's knee pain drug gets FDA nod, shares hit life high

* Osteoarthritis drug market to hit $3.5 bln by 2026 - GlobalData

07 Oct 2017

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

07 Oct 2017

Flexion's knee pain drug gets FDA nod

Oct 6 Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

07 Oct 2017

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - ‍on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

15 Sep 2017

BRIEF-Flexion Therapeutics qtrly loss per share $0.91

* Flexion therapeutics reports second quarter 2017 financial results and recent business highlights

09 Aug 2017

Earnings vs. Estimates